1. DNA methylation is an epigenetic process involved in development, aging, and cancer.
2. DNMT3A is a de novo DNA methyltransferase that has recently gained relevance due to its frequent mutations in various blood tumors.
3. This article discusses the biology of DNMT3A and its role in controlling hematopoietic fate decisions, how mutated DNMT3A promotes leukemogenesis, and the clinical relevance of DNMT3A mutations in hematological malignancies.
This article appears to be reliable and trustworthy as it provides evidence-based information on the role of DNMT3A in leukemia. The article cites relevant studies to support its claims such as Feinberg and Vogelstein (1983), Jones and Laird (1999), Okano et al (1998), Issa et al (1993), Robertson et al (1999), Mizuno et al (2001), Girault et al (2003), Oh et al (2007), Rahman et al (2010), Gao et al (2011) and Yang et al (2015). Furthermore, the article seems to be unbiased or one-sided; it presents both sides of the argument equally by discussing both the positive effects of mutated DNMT3A on leukemogenesis as well as their potential negative effects on prognosis for AML patients. The article also does not appear to contain any promotional content or favor any particular viewpoint or opinion; instead, it provides an objective overview of the current state of knowledge regarding DNMT3A mutations in leukemia without taking a clear stance on any specific issues or topics related to this subject. Additionally, throughout the article risks associated with DNMT3A mutations are noted which allows readers to gain a comprehensive understanding of this topic from all angles and perspectives.